<DOC>
	<DOCNO>NCT00385177</DOCNO>
	<brief_summary>This Phase 1 open-label study SN2310 Injectable Emulsion patient advance solid malignancy . The study design determine maximum tolerate dose dose-limiting toxicity SN2310 Injectable Emulsion , characterize pharmacokinetics SN2310 SN-38 follow intravenous administration SN2310 Injectable Emulsion . Additionally , evaluation side effect function dose , observation anti-tumor effect SN2310 Injectable Emulsion make .</brief_summary>
	<brief_title>Phase 1 Dose Escalation Study SN2310 Injectable Emulsion Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This Phase 1 open-label study SN2310 Injectable Emulsion patient advance solid malignancy fail conventional therapy . SN2310 Injectable Emulsion administer intravenously every 21 day . The study design determine maximum tolerate dose dose-limiting toxicity SN2310 Injectable Emulsion ; characterize pharmacokinetics SN2310 SN-38 follow intravenous administration SN2310 Injectable Emulsion ; evaluate side effect function dose level ; , observe anti-tumor effect SN2310 Injectable Emulsion .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Pelvic Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis solid tumor disease progression despite standard therapy and/or solid therapeutic option exists ANC &gt; 1,500 cell/mm3 , platelet &gt; 100,000/mm3 Hgb &gt; 9 g/dl At least one unidimensionally measurable lesion per RECIST Negative serum urine pregnancy test , female childbearing potential Female pregnant lactate History chronic diarrhea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>